US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Esperion Therapeutics, Inc. - Common Stock (NQ:ESPR)

3.180 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Esperion Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
Why Is Esperion Therapeutics Stock Sinking Premarket Today? ↗
Via Stocktwits
News headline image
Esperion Announces Pricing of Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Esperion Announces Proposed Public Offering of Common Stock
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
What to Expect from Esperion Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Top 2 Health Care Stocks That May Plunge This Month ↗
 
Via Benzinga
News headline image
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming September Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion (ESPR) Q2 Revenue Jumps 12% ↗
Via The Motley Fool
News headline image
Esperion Therapeutics Inc (NASDAQ:ESPR) Beats Q2 2025 Revenue Forecasts and Reduces Losses Amid Strong Prescription Growth ↗
Esperion Therapeutics (ESPR) beats Q2 2025 revenue estimates with $82.4M, narrows losses, and sees 42% U.S. sales growth. Stock surges 12% pre-market. 
Via Chartmill
News headline image
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Report Second Quarter 2025 Financial Results on August 5
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Appoints Craig Thompson to Board of Directors
Brings More Than Twenty Years of Biopharmaceutical Leadership Experience 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in Upcoming June Investor Conferences
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
From Esperion Therapeutics, Inc.
Via GlobeNewswire
News headline image
Esperion Reports First Quarter 2025 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >